26 results on '"Nektar Therapeutics -- Forecasts and trends -- Product development"'
Search Results
2. NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
3. B-Cell Lymphomas Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Oncternal, ZAI Lab, Pfizer, SystImmune, Vincerx, InnoCare
4. Bladder Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | RemeGen, UroGen, Asieris, Pfizer, Roche, Protara, Emtora
5. Metastatic Urothelial Carcinoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | PharmaMar, Ectin, Exelixis, Merck, Seagen
6. NK Cell Therapy Pipeline Booms as 100+ Companies likely to Enter in the Treatment Domain | Major Companies - Cantargia, Cellid, Celyad, and Others
7. 150+ Active Companies working to develop 150+ Pipeline Therapies for Head and Neck Cancer Treatment Landscape | Major Companies - GlaxoSmithKline, Takeda, Merck, AstraZeneca, and Others
8. 100+ Active Companies working to Develop 185+ Pipeline Therapies for NK Cell Therapy Treatment
9. Urothelial Carcinoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products
10. Head and Neck Cancer Pipeline Report: Inactive Products Analysis (Dormant and Terminated) along with the reasons for Dormancy and Discontinuation
11. Metastatic Renal Cell Carcinoma Pipeline Analysis Novel 40+ Pipeline Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
12. NK Cell Therapy Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
13. Metastatic Renal Cell Carcinoma Pipeline Analysis Demonstrates Novel 40+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
14. 100+ Leading Multiple Myeloma Pipeline Companies are working to improve the treatment landscape
15. Urothelial Carcinoma Pipeline Insight and Clinical Trials Analysis and NDA Approvals | 40+ Companies and 50+ Drugs
16. Metastatic Melanoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
17. Head and Neck Cancer Pipeline, Clinical Trial Analysis and NDA Approvals | 150+ Companies and 150+ Drugs
18. Head and Neck Cancer Pipeline Assessment, 2022 | Latest FDA, EMA, and PMDA Approvals, Emerging Therapies, Ongoing Clinical Trials | Galectin, Cue Biopharma, CEL-SCI Corporation, PDS Biotech
19. Head and Neck Cancer Clinical Trial Pipeline: Analysis of 130+ Key Companies Working in the Domain | DelveInsight
20. Metastatic Renal Cell Carcinoma Clinical Trials Pipeline Landscape Analysis of 45+ Companies by DelveInsight
21. Metastatic Renal Cell Carcinoma Clinical Trials Pipeline Landscape Analysis of 45+ Companies by DelveInsight
22. Bladder Cancer Therapeutics Pipeline Assessment | Insights into the Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, Treatment Outlook, and Key Companies
23. Muscle Invasive Bladder Cancer Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical Trials, Emerging Therapies, Treatment Algorithm
24. Urothelial Carcinoma Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight
25. Urothelial Carcinoma Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight
26. Advanced Urothelial Carcinoma Pipeline Outlook - Insights Into the Emerging Therapies, Clinical Trials, and Treatment Outlook | Key Companies - Genentech, AstraZeneca, Immunomedics, Seagen, and Others
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.